Original Article
Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A
N Engl J Med 2005; 353:1105-1113September 15, 2005
- Abstract
Background
Medullary thyroid carcinoma is the most common cause of death in patients with multiple endocrine neoplasia (MEN) type 2A (MEN-2A) or type 2B or familial medullary thyroid carcinoma. We sought to determine whether total thyroidectomy in asymptomatic young members of kindreds with MEN-2A who had a mutated allele of the RET proto-oncogene could prevent or cure medullary thyroid carcinoma.
Methods
A total of 50 patients 19 years of age or younger who were consecutively identified through a genetic screening program as carriers of a RET mutation characteristic of MEN-2A underwent total thyroidectomy. Five to 10 years after the surgery, each patient was evaluated by physical examination and by determination of plasma calcitonin levels after stimulation with provocative agents.
Results
In 44 of the 50 patients, basal and stimulated plasma calcitonin levels were at or below the limits of detection of the assay (proportion, 0.88; 95 percent confidence interval, 0.76 to 0.95). Two patients had basal and stimulated plasma calcitonin levels above the normal range. Stimulated plasma calcitonin levels had increased but remained within the normal range in four patients. The data suggest that there was a lower incidence of persistent or recurrent disease in children who underwent total thyroidectomy before eight years of age and in children in whom there were no metastases to cervical lymph nodes.
Conclusions
In this study, young patients identified by direct DNA analysis as carriers of a RET mutation characteristic of MEN-2A had no evidence of persistent or recurrent medullary thyroid carcinoma five or more years after total thyroidectomy. A longer period of evaluation will be necessary to confirm that they are cured.
Media in This Article
Figure 1
Calcium–Pentagastrin Stimulation Testing.Table 1
Characteristics of the Patients.Article Activity
- Article
Medullary thyroid carcinoma, a cancer of the parafollicular (C) cells, develops in virtually all patients with multiple endocrine neoplasia (MEN) type 2A (MEN-2A) or type 2B (MEN-2B) and in those with familial medullary thyroid carcinoma.1-3 Medullary thyroid carcinoma is the most common cause of death in patients with these endocrinopathies, and total thyroidectomy that is performed before medullary thyroid carcinoma develops or spreads beyond the gland is currently the only curative treatment.
Over time, patients with MEN-2A, MEN-2B, or familial medullary thyroid carcinoma develop a spectrum of C-cell disorders, beginning with C-cell hyperplasia and progressing to intrathyroidal medullary thyroid carcinoma, regional lymph-node metastases, and distant metastases.4 C cells secrete the hormone calcitonin, and blood levels of this polypeptide serve as a sensitive tumor marker as well as an indicator of the C-cell mass.5 Intravenously administered calcium and pentagastrin are potent calcitonin secretagogues that markedly enhance the sensitivity of the calcitonin assay.6
In the early 1990s, it was shown that mutations in the RET proto-oncogene cause MEN-2A, MEN-2B, and familial medullary thyroid carcinoma.7-9 Thus, by direct DNA analysis, it is possible to identify persons within kindreds with these syndromes who have inherited a mutated RET allele and in whom medullary thyroid carcinoma is destined to develop. This discovery changed the treatment of patients at risk for hereditary medullary thyroid carcinoma, since it provided a rationale to perform thyroidectomy either before medullary thyroid carcinoma developed or while the cancer was confined to the gland.10
On the basis of clinical evaluation and biochemical testing, we sought to determine whether young patients with the MEN-2A genotype who had no physical evidence of medullary thyroid carcinoma were free of disease five or more years after total thyroidectomy. We also sought to determine whether the outcome of surgery is related to the specific RET codon mutation, the preoperative stimulated plasma calcitonin level, the age of the patient at the time of total thyroidectomy, the histologic status of the resected thyroid gland, the presence or absence of cervical lymph-node metastases, or all of these factors.
Methods
Subjects
In 1993, our clinic initiated a genetic screening program for patients at risk for MEN-2A, MEN-2B, and familial medullary thyroid carcinoma. We identified 85 patients who had inherited a mutated allele that is characteristic of MEN-2A. Each patient underwent total thyroidectomy, with the exception of two children (a 9-year-old child with cerebral palsy and a 12-year-old child with autism) whose parents did not consent to surgery.
Our study concerns the 50 patients consecutively identified as having MEN-2A who were 19 years of age or younger (range, 3 to 19 years; mean, 10 years) at the time of total thyroidectomy and who were evaluated for evidence of medullary thyroid carcinoma at least 5 years postoperatively (range, 5 to 10 years; mean, 7 years). Excluded from the analysis were 24 patients who were older than 19 years of age at the time of total thyroidectomy and 9 patients who, although younger than 19 years at the time of surgery, were evaluated only one to four years postoperatively.
The protocols and informed-consent documents for genetic testing, genetic counseling, total thyroidectomy, and postoperative evaluation were reviewed and approved by the institutional review boards at the Washington University School of Medicine and the Duke University School of Medicine. All patients and legal guardians of patients who were minors gave written informed consent to participate in the study.
Clinical and Hormonal Assessment
For each patient, a medical history was obtained and a physical examination performed. In addition, plasma calcitonin levels were determined before and after provocative testing with calcium and pentagastrin.6 Pentagastrin (Peptavlon) was obtained from Wyeth–Ayerst until 1999 and thereafter from Cambridge Laboratories. Five or more years after total thyroidectomy, all patients were evaluated by physical examination and by the determination of plasma calcitonin levels; 48 patients were tested both before and after the combined infusion of calcium and pentagastrin, 1 patient was tested with calcium gluconate alone, and 1 was tested with pentagastrin alone.
Plasma calcitonin levels were determined with the use of assay kits from the Nichols Institute (Quest Diagnostics). Until 1996, calcitonin levels were determined with the use of a radioimmunoassay; thereafter, these measurements (including studies performed five or more years after total thyroidectomy) were made by a chemiluminescent assay. In all patients, postoperative blood calcium levels were determined by atomic absorption analysis.
Genetic Testing
DNA was isolated from peripheral-blood leukocyte samples with the use of standard methods. Patients and at-risk family members were screened for mutations in the RET proto-oncogene with the use of polymerase chain reaction (PCR) amplification and direct sequencing for exons 10, 11, 13, and 14, which are known to harbor pathogenic MEN-associated mutations.11-13 Each exon region was amplified with the use of two different pairs of PCR primers to avoid any possible amplification bias, and the DNA sequence from both strands was determined. PCR amplification of exon 16, coupled with restriction-enzyme digestion, was used to detect the codon 918 mutation associated with MEN-2B. Some point mutations in exons 10, 11, 13, and 14 also involve restriction sites, and for these, restriction-fragment–length polymorphism assays were substituted for PCR sequencing of DNA.9,11,13 We required concordance of the sequence data or restriction-fragment–length polymorphism patterns from both PCR products, both DNA strands, or all of these in order to report test findings.
Operative Technique
One of four surgeons performed a total thyroidectomy on each of the 50 patients. Each surgeon followed an established operative protocol consisting of removal of the entire thyroid gland (including the posterior capsule) and resection of lymph nodes in the central zone of the neck (from the hyoid bone to the thoracic inlet and laterally to the carotid arteries). The parathyroid glands were removed and then placed as intramuscular autografts, either in the nondominant forearm (if the patient had a RET mutation associated with a high incidence of parathyroid hyperplasia) or in the neck.14
Postoperative Management
Patients began taking oral calcium and vitamin D after total thyroidectomy and were discharged after the serum calcium level was documented to be normal or near normal and after a calcium–pentagastrin stimulation test was performed. Thereafter, patients were evaluated by our group in collaboration with the patients' referring physicians. Our group performed annual physical examinations and intermittent calcitonin testing after thyroidectomy.
Histologic Analysis
The thyroid glands and soft tissues from the lymph-node dissection in the central zone were fixed in formalin and embedded in paraffin. Sections stained with hematoxylin and eosin were evaluated for the presence of medullary thyroid carcinoma according to the criteria of Wolfe et al.4 and Mendelsohn et al.15
Statistical Analysis
The marginal binomial proportions were estimated with the use of empirical proportions and exact Clopper–Pearson interval estimators.16 The discrepancy between two continuous distributions was assessed with the use of the exact Wilcoxon rank-sum test.17 The discrepancy between two binomial proportions was assessed with the use of Fisher's exact test for contingency tables.18 The association between clinical covariates and binomial responses was investigated with the use of conditional logistic regression.19 All P values and confidence intervals are two-sided and have not been adjusted to account for multiplicity.
The conditional logistic-regression analyses were carried out with the use of LogXact software (version 5, Cytel). All other statistical analyses were carried out with the use of R software (version 1.9.1, R Project for Statistical Computing). The implementation of the exact Wilcoxon rank-sum test17 found in the 0.8-8 version of the exactRankTests was used.
The study design, data gathering, data analysis, and writing of the manuscript were carried out by the study investigators.
Results
Direct DNA Analysis for RET Mutations
RET mutations in the 50 patients with MEN-2A were found at codons 609 (3 patients), 611 (1 patient), 618 (11 patients), 620 (16 patients), and 634 (19 patients). Of the six patients who had evidence of persistent or recurrent medullary thyroid carcinoma after total thyroidectomy, two had mutations in codon 618, 620, or 634. There was no statistical evidence that the presence of persistent or recurrent medullary thyroid carcinoma was dependent on the specific codon mutation (P=0.92).
Pathology
Thyroid Gland
On gross and histologic examination of the thyroid glands, 17 patients (median age, 6 years) had either no evident disease or isolated C-cell hyperplasia, whereas 33 patients (median age, 10 years) had microscopic or macroscopic evidence of medullary thyroid carcinoma. The age distribution of patients with either no evident disease or isolated C-cell hyperplasia differed from that of patients with medullary thyroid carcinoma (P=0.02).
Lymph Nodes
Lymph nodes from the central zone of the neck were resected in all but 1 of the 50 patients. The number of nodes removed ranged from 3 to 30 (mean, 10.9 nodes per patient). Metastases to regional nodes were found in three patients (one at 10 years of age, with 2 of 6 nodes positive, and two at 11 years of age, with 3 of 11 nodes positive and 1 of 8 nodes positive, respectively). In two of the three patients with metastases to regional nodes, plasma calcitonin levels became elevated during the postoperative period, indicating persistent or recurrent disease. The data suggest that patients with negative nodes had a lower incidence of persistent or recurrent medullary thyroid carcinoma than those with positive nodes (P=0.04).
Plasma Calcitonin Levels
Preoperative Levels
The age distribution of the 27 patients (median age, 11 years) with elevated preoperative plasma calcitonin levels after stimulation appeared to differ, if slightly, from that of the 23 patients (median age, 7 years) with normal preoperative levels (P=0.05).
Postoperative Levels
Forty-four of the 50 patients evaluated after total thyroidectomy had no evidence of persistent or recurrent disease, as evidenced by normal findings on a physical examination and by plasma calcitonin levels that were at or below the limits of detection of the assay before and after calcium and pentagastrin stimulation (proportion, 0.88; 95 percent confidence interval, 0.76 to 0.95) (Figure 1AFigure 1
Calcium–Pentagastrin Stimulation Testing.). In the remaining six patients, basal or stimulated plasma calcitonin levels became elevated after total thyroidectomy, indicating persistent or recurrent medullary thyroid carcinoma. Patient 24 had basal plasma calcitonin values that exceeded the normal range in the immediate postoperative period and that continued to increase on subsequent testing (Figure 1B and Table 1Table 1Characteristics of the Patients. and Table 2Table 2
Plasma Calcitonin Levels before and after Calcium–Pentagastrin Stimulation in Patients with Persistent or Recurrent Disease after Surgery.). Stimulated plasma calcitonin values in this patient increased but remained within the normal range immediately after total thyroidectomy and rose above the normal range six years later.Patient 13 had an elevated basal plasma calcitonin level three years after total thyroidectomy (Table 1 and Table 2). The stimulated plasma calcitonin levels then increased gradually and reached levels above the normal range nine years after total thyroidectomy.
In Patients 1, 5, 19, and 36, basal plasma calcitonin levels were undetectable at all testing points after total thyroidectomy (Table 1 and Table 2). However, the stimulated levels were elevated above basal levels but within the normal range. In Patient 1, the stimulated plasma calcitonin levels rose progressively but remained within the normal range five and eight years after total thyroidectomy. Nine years after surgery, Patient 19 had stimulated plasma calcitonin levels that had increased but that remained within the normal range. In Patient 5, stimulated plasma calcitonin levels had increased minimally above the basal level at five years. Patient 36 had undetectable stimulated plasma calcitonin levels three years after total thyroidectomy but a minimal increase above the basal level at six years.
Timing of Surgery
Of 28 patients who were 8 years of age or older (median age, 13.5 years) at the time of total thyroidectomy, postoperative stimulated plasma calcitonin levels subsequently became elevated in 6. Postoperative stimulated levels remained undetectable in 22 patients who were 7 years of age or younger (median age, 5.5 years) at the time of total thyroidectomy (P=0.03). The specific cutoff age of eight years was chosen post hoc, and since the P value presented has not been adjusted accordingly, the observation should be interpreted with caution.
We attempted to perform a multivariate logistic analysis, with evidence of persistent or recurrent disease as the response and, as candidate covariates, patients' age at the time of thyroidectomy, the specific RET codon mutation, thyroid histologic findings, preoperative calcitonin values, and regional lymph-node metastases. Because of the sparseness of the covariate structure, the resulting estimates were deemed to be unreliable and are not presented in this article.
Parathyroid Function
The postoperative serum calcium levels were evaluated at least one year postoperatively in all patients who underwent total thyroidectomy and dissection of the lymph nodes in the central neck zone. Serum calcium levels were normal in 47 of the 50 patients (94 percent); however, in 3 patients (ages four, four, and six years at the time of surgery), calcium and vitamin D supplements were required to maintain the serum calcium levels within or near the normal range.
Discussion
With the availability of molecular techniques that identify persons in whom a specific solid-organ cancer is destined to develop, we have had the opportunity to test the hypothesis that such a cancer can be prevented or cured by preemptive removal of the organ, either before the cancer develops or while it is in situ. In order to confirm this hypothesis, several conditions must be met: there must be a reliable method of identifying patients in whom cancer in a specific organ will develop, the organ must be expendable or its function amenable to suitable replacement, removal of the organ must pose minimal risk to the patient, and there must be a sensitive method to determine whether the patient has been rendered free of disease and remains so after removal of the organ.
The medullary thyroid carcinoma associated with the type 2 MEN syndromes meets each of these criteria. Direct DNA analysis for mutations in the RET proto-oncogene can identify members of kindreds with MEN-2A, MEN-2B, or familial medullary thyroid carcinoma in whom thyroid cancer will develop. Thyroxine can replace the function of the removed gland. Elective total thyroidectomy is a standard operative procedure associated with minimal morbidity and virtually no mortality. The medullary thyroid carcinoma cells secrete calcitonin, which serves as an excellent tumor marker that indicates persistent or recurrent medullary thyroid carcinoma after total thyroidectomy.
In our study, we established strict criteria for determining whether young patients with MEN-2A were free of disease after total thyroidectomy. Each of the 50 patients was evaluated by physical examination and calcitonin testing (with calcium and pentagastrin stimulation in all but 2 patients) five or more years after removal of the thyroid gland. A plasma calcitonin value above the normal basal level at a single time point after provocative testing was considered evidence of persistent or recurrent medullary thyroid carcinoma, even if the value fell within the range of plasma calcitonin values found in normal persons.
In 44 of the patients (88 percent), and in all of those who underwent total thyroidectomy before eight years of age, there was no evidence of persistent or recurrent medullary thyroid carcinoma. Six patients who had increased basal or stimulated plasma calcitonin levels postoperatively were considered to have residual medullary thyroid carcinoma. Moderate elevations in plasma calcitonin levels have been reported in association with certain malignant tumors and benign inflammatory conditions, none of which were present in our patients.20-23 The progressive increases in stimulated plasma calcitonin levels after total thyroidectomy in patients with medullary thyroid carcinoma are characteristic of an enlarging C-cell mass due to persistent or recurrent disease.
We evaluated the potential effects on outcome of several factors: age at the time of surgery, the histologic status of the resected thyroid gland (no evident disease or isolated C-cell hyperplasia vs. evidence of medullary thyroid carcinoma), the presence or absence of lymph-node metastases, the preoperative stimulated plasma calcitonin level, and a specific RET codon mutation. The data from our study suggest that there was a lower incidence of persistent or recurrent disease in children who underwent total thyroidectomy before eight years of age and who had no metastases to cervical lymph nodes.
The most important consideration with regard to children known to have inherited a mutated RET allele, which is characteristic of MEN-2A, is the timing of the thyroidectomy. Currently, our practice is to perform total thyroidectomy when the child is between five and eight years of age, regardless of the RET codon mutation. In patients of this age, it is probably unnecessary to perform a central-zone lymph-node dissection, since none of our patients younger than 11 years of age and none of the patients younger than 14 years described by Machens et al.24 had lymph-node metastases at the time of total thyroidectomy. It should be noted, however, that Graham and colleagues reported lymph-node metastases in a six-year-old child with MEN-2A who underwent total thyroidectomy on the basis of increased stimulated plasma calcitonin levels.25 Furthermore, one would expect the incidence of persistent hypocalcemia to be lower in children in whom central-zone lymph-node dissection is not performed at the time of total thyroidectomy than in those in whom it is performed.
Although the data from our study are encouraging, definitive guidelines for the operative treatment of children with MEN-2A, MEN-2B, and familial medullary thyroid carcinoma will require that large numbers of patients be evaluated for a longer period postoperatively to confirm that prophylactic total thyroidectomy prevents or cures hereditary medullary thyroid carcinoma.
Supported by grants (PO1CA53524 and MO1RR00036) from the National Institutes of Health.
Source Information
From the Department of Surgery (M.A.S., S.A.W.) and the Department of Biostatistics and Bioinformatics (K.O.), Duke University School of Medicine, Durham, N.C.; and the Department of Surgery, Washington University School of Medicine, St. Louis (J.A.M., W.G.D., M.K.D.).
Address reprint requests to Dr. Wells at Box 3285, Duke University Medical Center, Durham, NC 27710, or at wells029@mc.duke.edu.
- References
References
1
Steiner AL ,Goodman AD ,Powers SR . Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia type 2. Medicine (Baltimore) 1968;17:371-4082
Chong GC ,Beahrs OH ,Sizemore GW ,Woolner LH . Medullary carcinoma of the thyroid gland. Cancer 1975;35:695-704
CrossRef | Web of Science | Medline3
Farndon JR ,Leight GS ,Dilley WG , et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278-281
CrossRef | Web of Science | Medline4
Wolfe HJ ,Melvin KEW ,Cervi-Skinner SJ , et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-441
Full Text | Web of Science | Medline5
Pomares FJ ,Rodriguez JM ,Nicolas F , et al. Presurgical assessment of the tumor burden of familial medullary thyroid carcinoma by calcitonin testing. J Am Coll Surg 2002;195:630-634
CrossRef | Web of Science | Medline6
Wells SA Jr ,Baylin SB ,Linehan WM ,Farrell RE ,Cox EB ,Cooper CW . Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 1978;188:139-141
CrossRef | Web of Science | Medline7
Donis-Keller H ,Dou S ,Chi D , et al. Mutations in the RET proto-oncogene are associated with MEN-2A and FMTC. Hum Mol Genet 1993;2:851-856
CrossRef | Web of Science | Medline8
Mulligan LM ,Kwok JBH ,Healey CS , et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460
CrossRef | Web of Science | Medline9
Carlson KM ,Dou S ,Chi D , et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994;91:1579-1583
CrossRef | Web of Science | Medline10
Wells SA Jr ,Chi DD ,Toshima K , et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-250
CrossRef | Web of Science | Medline11
Chi DD ,Toshima K ,Donis-Keller H ,Wells SA Jr . Predictive testing for multiple endocrine neoplasia type 2A (MEN-2A) based on detection of mutations in the RET protooncogene. Surgery 1994;116:124-133
Web of Science | Medline12
Bolino A ,Schuffenecker I ,Luo Y , et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995;10:2415-2419
Web of Science | Medline13
Human Genome Mutation Database Cardiff. RET protooncogene. (Accessed August 22, 2005, at http://archive.uwcm.ac.uk/uwcm/mg/search/120346.html.)
14
Mulligan LM ,Eng C ,Healey CS , et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN-2A and FMTC. Nat Genet 1994;6:70-74
CrossRef | Web of Science | Medline15
Mendelsohn G ,Eggleston JC ,Weisburger WR ,Gann DS ,Baylin SB . Calcitonin and histaminase in C-cell hyperplasia and medullary thyroid carcinoma: a light microscopic and immunohistochemical study. Am J Pathol 1978;92:35-43
Web of Science | Medline16
Clopper CJ ,Pearson ES . The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413
CrossRef | Web of Science17
Hajek J, Sidak Z, Sen PK. Theory of rank tests. 2nd ed. San Diego, Calif.: Academic Press, 1999:96-7.
18
Cox DR, Snell EJ. Analysis of binary data. 2nd ed. New York: Chapman and Hall, 1989:48.
19
McCullagh P, Nelder JA. Generalized linear models. 2nd ed. New York: Chapman and Hall, 1989:248-55.
20
Roos BA ,Lindall AW ,Baylin SB , et al. Plasma immunoreactive calcitonin in lung cancer. Endocr Res Commun 1979;6:169-190
CrossRef | Medline21
Whang KT ,Steinwald PM ,White JC , et al. Related serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998;83:3296-3301
CrossRef | Web of Science | Medline22
Milhaud G ,Calmette C ,Taboulet J ,Julienne A ,Moukhtar MS . Hypersecretion of calcitonin in neoplastic conditions. Lancet 1974;1:462-463
CrossRef | Web of Science | Medline23
di Sant'Agnese PA . Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287-296
CrossRef | Web of Science | Medline24
Machens A ,Niccoli-Sire P ,Hoegel J , et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525
Full Text | Web of Science | Medline25
Graham SM ,Genel M ,Touloukian RJ ,Barwick KW ,Gertner JM ,Torony C . Provocative testing for occult medullary carcinoma of the thyroid: findings in seven children with multiple endocrine neoplasia type IIa. J Pediatr Surg 1987;22:501-503
CrossRef | Web of Science | Medline
- Citing Articles (89)
Citing Articles
1
Diana L. Diesen, Michael A. Skinner. (2012) Pediatric thyroid cancer. Seminars in Pediatric Surgery 21:1, 44-50
CrossRef2
Lee F. Starker, Tobias Åkerström, William D. Long, Alberto Delgado-Verdugo, Patricia Donovan, Robert Udelsman, Richard P. Lifton, Tobias Carling. (2011) Frequent Germ-Line Mutations of the MEN1, CASR, and HRPT2/CDC73 Genes in Young Patients with Clinically Non-familial Primary Hyperparathyroidism. Hormones and Cancer
CrossRef3
Ping Zhou, Jian Liu, Shao-Wen Cheng, Bing Wang, Rong Yang, Ling Peng. (2011) Hereditary medullary thyroid carcinoma: the management dilemma. Familial Cancer
CrossRef4
Steven G. Waguespack, Thereasa A. Rich, Nancy D. Perrier, Camilo Jimenez, Gilbert J. Cote. (2011) Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nature Reviews Endocrinology 7:10, 596-607
CrossRef5
H. Prazeres, J. P. Couto, F. Rodrigues, J. Vinagre, J. Torres, V. Trovisco, T. C. Martins, M. Sobrinho-Simoes, P. Soares. (2011) In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocrine Related Cancer 18:4, 401-412
CrossRef6
Dhalapathy Sadacharan, Gaurav Agarwal. (2011) Response to “Long-term outcome of ‘prophylactic therapy’ for familial medullary thyroid cancer (MTC)”. Surgery 149:6, 851
CrossRef7
Emily Gallagher, Derek LeRoith. 2011. Principles of Translational Medicine and Applications to Thyroid Cancer Investigation. , 1-10.
CrossRef8
Marie-Ellen Sarvida, M. Sue O’Dorisio. (2011) Neuroendocrine Tumors in Children and Young Adults: Rare or Not So Rare. Endocrinology & Metabolism Clinics of North America 40:1, 65-80
CrossRef9
Anna Ray Laury, Massimo Bongiovanni, Jean-Christophe Tille, Harry Kozakewich, Vânia Nosé. (2011) Thyroid Pathology in PTEN -Hamartoma Tumor Syndrome: Characteristic Findings of a Distinct Entity. Thyroid 21:2, 135-144
CrossRef10
Hugo Prazeres, Joana Torres, Fernando Rodrigues, Joana P. Couto, João Vinagre, Manuel Sobrinho-Simões, Paula Soares. (2011) How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. Journal of Thyroid Research 2011, 1-10
CrossRef11
S Mukherjee, D Zakalik. (2011) RET codon 804 mutations in multiple endocrine neoplasia 2: genotype-phenotype correlations and implications in clinical management. Clinical Genetics 79:1, 1-16
CrossRef12
MSara Rosenthal, DouglasS Diekema. (2011) Pediatric Ethics Guidelines for Hereditary Medullary Thyroid Cancer. International Journal of Pediatric Endocrinology 2011:1, 847603
CrossRef13
Deepak T. Abraham, Tsu-Hui Low, Marinella Messina, Nicole Jackson, Anthony Gill, Angela S. Chou, Leigh Delbridge, Diana Learoyd, Bruce G. Robinson, Stan Sidhu, Mark Sywak. (2011) Medullary Thyroid Carcinoma: Long-Term Outcomes of Surgical Treatment. Annals of Surgical Oncology 18:1, 219-225
CrossRef14
Elizabeth G. Grubbs, Steven G. Waguespack, Thereasa A. Rich, Yan Xing, Anita K. Ying, Douglas B. Evans, Jeffrey E. Lee, Nancy D. Perrier. (2010) Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A?. Surgery 148:6, 1302-1310
CrossRef15
Joel T. Adler, Rebecca S. Sippel, Herbert Chen. (2010) New Trends in Parathyroid Surgery. Current Problems in Surgery 47:12, 958-1017
CrossRef16
Ashley E. Jones, Edythe A. Albano, Mark A. Lovell, Stephen P. Hunger. (2010) Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A. Pediatric Blood & Cancer 55:6, 1213-1216
CrossRef17
Friedhelm Raue, Karin Frank-Raue. (2010) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. Expert Review of Endocrinology & Metabolism 5:6, 867-874
CrossRef18
Ismail Jatoi, John R. Benson, Siong-Seng Liau, Yijun Chen, Robin M. Cisco, Jeffrey A. Norton, Jeffrey F. Moley, Katherine W. Khalifeh, Michael A. Choti. (2010) The Role of Surgery in Cancer Prevention. Current Problems in Surgery 47:10, 750-830
CrossRef19
Friedhelm Raue, Karin Frank-Raue. (2010) Update multiple endocrine neoplasia type 2. Familial Cancer 9:3, 449-457
CrossRef20
Herbert Chen, Rebecca S. Sippel, M. Sue O'Dorisio, Aaron I. Vinik, Ricardo V. Lloyd, Karel Pacak. (2010) The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas 39:6, 775-783
CrossRef21
S. Müller, D. Poehnert, J. A. Müller, G. W. F. Scheumann, M. Koch, R. Lück. (2010) Regulatory T Cells in Peripheral Blood, Lymph Node, and Thyroid Tissue in Patients with Medullary Thyroid Carcinoma. World Journal of Surgery 34:7, 1481-1487
CrossRef22
Nelson Wohllk, Heiko Schweizer, Zoran Erlic, Kurt Werner Schmid, Martin K. Walz, Friedhelm Raue, Hartmut P.H. Neumann. (2010) Multiple endocrine neoplasia type 2. Best Practice & Research Clinical Endocrinology & Metabolism 24:3, 371-387
CrossRef23
Jennifer M. J. Schreinemakers, Menno R. Vriens, Gerlof D. Valk, Jan-Willem B. Groot, John T. Plukker, Klaas (N.) M. A. Bax, Jaap F. Hamming, Rob B. Luijt, Daniel C. Aronson, Inne H. M. Borel Rinkes. (2010) Factors Predicting Outcome of Total Thyroidectomy in Young Patients with Multiple Endocrine Neoplasia Type 2: A Nationwide Long-Term Follow-up Study. World Journal of Surgery 34:4, 852-860
CrossRef24
Neil S. Tolley, Asit Arora, Christos Georgalas. 2010. Surgical Management of Thyroid Cancer. , 117-124.
CrossRef25
Steven G. Waguespack, Thereasa A. Rich. (2010) Multiple endocrine syndrome type 2B in early childhood. CancerNA-NA
CrossRef26
Menno R. Vriens, Insoo Suh, Willieford Moses, Electron Kebebew. (2009) Clinical Features and Genetic Predisposition to Hereditary Nonmedullary Thyroid Cancer. Thyroid 19:12, 1343-1349
CrossRef27
H. Dralle, K. Lorenz, A. Machens. (2009) Chirurgie der Schilddrüsenkarzinome. Der Chirurg 80:11, 1069-1084
CrossRef28
Elisabeth Schellhaas, Charlotte König, Karin Frank-Raue, Heinz-J. Buhr, Hubert G. Hotz. (2009) Long-term outcome of “prophylactic therapy” for familial medullary thyroid cancer. Surgery 146:5, 906-912
CrossRef29
Tricia A. Moo-Young, Amber L. Traugott, Jeffrey F. Moley. (2009) Sporadic and Familial Medullary Thyroid Carcinoma: State of the Art. Surgical Clinics of North America 89:5, 1193-1204
CrossRef30
Andreas Machens, Kerstin Lorenz, Henning Dralle. (2009) Individualization of Lymph Node Dissection in RET (Rearranged During Transfection) Carriers at Risk for Medullary Thyroid Cancer. Annals of Surgery 250:2, 305-310
CrossRef31
A. Machens, K. Lorenz, H. Dralle. (2009) Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities. Journal of Internal Medicine 266:1, 114-125
CrossRef32
M K J Jaggard, C MacRae, S Ifeacho, S Robinson, N S Tolley. (2009) New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation. The Journal of Laryngology & Otology 123:07, 796
CrossRef33
M M Moura, B M Cavaco, A E Pinto, R Domingues, J R Santos, M O Cid, M J Bugalho, V Leite. (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. British Journal of Cancer 100:11, 1777-1783
CrossRef34
Richard T. Kloos (Chair), Charis Eng, Douglas B. Evans, Gary L. Francis, Robert F. Gagel, Hossein Gharib, Jeffrey F. Moley, Furio Pacini, Matthew D. Ringel, Martin Schlumberger, Samuel A. Wells. (2009) Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. Thyroid 19:6, 565-612
CrossRef35
Steven G. Waguespack. (2009) A Perspective from Pediatric Endocrinology on the Hereditary Medullary Thyroid Carcinoma Syndromes. Thyroid 19:6, 543-546
CrossRef36
Rebecca L. Margraf, David K. Crockett, Patti M.F. Krautscheid, Ryan Seamons, Fernanda R.O. Calderon, Carl T. Wittwer, Rong Mao. (2009) Multiple endocrine neoplasia type 2 RET protooncogene database: Repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Human Mutation 30:4, 548-556
CrossRef37
Anne-Paule Gimenez-Roqueplo. (2009) Genetics of chromaffin tumors. Expert Review of Endocrinology & Metabolism 4:2, 143-151
CrossRef38
P.E. Goretzki, D. Wirowski, K. Schwarz, P. Pohl, H. Böhner, A. Starke, B.J. Lammers. (2009) Indikation und Durchführung endokrin-chirurgischer Operationen. Der Chirurg 80:2, 122-129
CrossRef39
Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller-Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat Müller. (2009) Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. CancerNA-NA
CrossRef40
Jennifer L. Hunt. (2009) Molecular Alterations in Hereditary and Sporadic Thyroid and Parathyroid Diseases. Advances in Anatomic Pathology 16:1, 23-32
CrossRef41
Henning Dralle, Andreas Machens. (2008) Surgical approaches in thyroid cancer and lymph-node metastases. Best Practice & Research Clinical Endocrinology & Metabolism 22:6, 971-987
CrossRef42
Vânia Nosé. (2008) Familial Non-Medullary Thyroid Carcinoma: An Update. Endocrine Pathology 19:4, 226-240
CrossRef43
Márcia K.C. Puñales, Andreia Possatti da Rocha, Camila Meotti, Jorge L. Gross, Ana Luiza Maia. (2008) Clinical and Oncological Features of Children and Young Adults with Multiple Endocrine Neoplasia Type 2A. Thyroid 18:12, 1261-1268
CrossRef44
H. Dralle, A. Machens, K. Lorenz. (2008) Hereditäre Schilddrüsenkarzinome. Der Chirurg 79:11, 1017-1028
CrossRef45
Jorge Dotto, Vânia Nosé. (2008) Familial Thyroid Carcinoma. Advances in Anatomic Pathology 15:6, 332-349
CrossRef46
Robin M. Cisco, James M. Ford, Jeffrey A. Norton. (2008) Hereditary diffuse gastric cancer. Cancer 113:S7, 1850-1856
CrossRef47
Tawakalitu Oseni, Ismail Jatoi. (2008) An Overview of the Role of Prophylactic Surgery in the Management of Individuals with a Hereditary Cancer Predisposition. Surgical Clinics of North America 88:4, 739-758
CrossRef48
Maria Domenica Castellone, Massimo Santoro. (2008) Dysregulated RET Signaling in Thyroid Cancer. Endocrinology & Metabolism Clinics of North America 37:2, 363-374
CrossRef49
Y. N. You, V. T. Lakhani, S. A. Wells. (2008) Reply. World Journal of Surgery 32:6, 1221-1222
CrossRef50
Jessica E. Gosnell, Orlo H. Clark. (2008) Surgical Approaches to Thyroid Tumors. Endocrinology & Metabolism Clinics of North America 37:2, 437-455
CrossRef51
Alexandra E. Shields, Wylie Burke, Douglas E. Levy. (2008) Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genetics in Medicine 10:6, 404-414
CrossRef52
Maya B Lodish, Constantine A Stratakis. (2008) RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Review of Anticancer Therapy 8:4, 625-632
CrossRef53
Tsunehisa Tsuru, Takeshi Usui, Jun Tsuji, Sachiko Minamiguchi, Eisaku Mori, Hanae Hagiwara, Takashi Kimura, Tetsuya Tagami, Mitsuhide Naruse, Akira Shimatsu. (2008) Somatic Mutation of RET Proto-Oncogene in Sporadic Medullary Thyroid Carcinoma. The Endocrinologist 18:2, 55-59
CrossRef54
Yi Zhang, Anne Marie Van Hoven, Xiangbing Wang. (2007) Factitious Multiple Endocrine Neoplasia Type 2. The Endocrinologist 17:6, 299-301
CrossRef55
Y. Nancy You, Vipul Lakhani, Samuel A. Wells. (2007) New Directions in the Treatment of Thyroid Cancer. Journal of the American College of Surgeons 205:4, S45-S48
CrossRef56
Jennifer L. Hay, Hendrika W. Meischke, Deborah J. Bowen, Joni Mayer, Jeanne Shoveller, Nancy Press, Maryam Asgari, Marianne Berwick, Wylie Burke. (2007) Anticipating dissemination of cancer genomics in public health: A theoretical approach to psychosocial and behavioral challenges. Annals of Behavioral Medicine 34:3, 275-286
CrossRef57
Wylie Burke, Ronald L. Zimmern, Mark Kroese. (2007) Defining purpose: a key step in genetic test evaluation. Genetics in Medicine 9:10, 675-681
CrossRef58
Catherine Dinauer, Gary L. Francis. (2007) Thyroid Cancer in Children. Endocrinology & Metabolism Clinics of North America 36:3, 779-806
CrossRef59
Murat Faik Erdogan, Alptekin Gursoy, Sevim Gullu, Semih Aydintug, Babur Kucuk, Nilgun Baskal, Nuri Kamel, Wolfgang Hoppner, Gurbuz Erdogan. (2007) Clinical and Genetic Experience in Turkish Multiple Endocrine Neoplasia Type 2 Families. The Endocrinologist 17:5, 273-277
CrossRef60
Jennifer D Holman, Jonathan A Dyer. (2007) Genodermatoses with malignant potential. Current Opinion in Pediatrics 19:4, 446-454
CrossRef61
Jeffrey A. Norton, Christine M. Ham, Jacques Van Dam, R Brooke Jeffrey, Teri A. Longacre, David G. Huntsman, Nicki Chun, Allison W. Kurian, James M. Ford. (2007) CDH1 Truncating Mutations in the E-Cadherin Gene. Annals of Surgery 245:6, 873-879
CrossRef62
Terry C. Lairmore. (2007) From Genetic Testing to the Operating Room. World Journal of Surgery 31:5, 1002-1004
CrossRef63
Andreas Machens, Henning Dralle. (2007) Genotype-Phenotype Based Surgical Concept of Hereditary Medullary Thyroid Carcinoma. World Journal of Surgery 31:5, 957-968
CrossRef64
Rebecca S. Sippel, Nadine R. Caron, Orlo H. Clark. (2007) An Evidence-based Approach to Familial Nonmedullary Thyroid Cancer: Screening, Clinical Management, and Follow-up. World Journal of Surgery 31:5, 924-933
CrossRef65
Kenneth D. McMilin, Susmita Dasgupta. (2007) Allogeneic Transplantation and the Risk for Transmission of Genetic Disease: The Heritable Cancer Disorders. Stem Cells and Development 16:2, 191-212
CrossRef66
Y. Nancy You, Vipul T. Lakhani, Samuel A. Wells. (2007) The Role of Prophylactic Surgery in Cancer Prevention. World Journal of Surgery 31:3, 450-464
CrossRef67
Samuel W. Moore, Justus Appfelstaedt, Monique G. Zaahl. (2007) Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. Journal of Pediatric Surgery 42:2, 326-332
CrossRef68
Vipul T. Lakhani, Y. Nancy You, Samuel A. Wells. (2007) The Multiple Endocrine Neoplasia Syndromes. Annual Review of Medicine 58:1, 253-265
CrossRef69
Maria João Bugalho, Rita Domingues, Jorge Rosa Santos, Ana Luísa Catarino, Luís Sobrinho. (2007) Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141:1, 90-95
CrossRef70
E.L. Mazzaferri. (2007) Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A. Yearbook of Endocrinology 2007, 287-291
CrossRef71
Andreana Bütter, Julie Gagné, Ayman Al-Jazaeri, Mohammad Ali Emran, Cheri Deal, Dickens St-Vil. (2007) Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. Journal of Pediatric Surgery 42:1, 203-206
CrossRef72
P.J. Loehrer. (2007) Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A. Yearbook of Oncology 2007, 335-337
CrossRef73
Francis D. Moore. (2006) Inherited aspects of papillary thyroid carcinoma. Journal of Surgical Oncology 94:8, 719-724
CrossRef74
Elizabeth A. Fialkowski, Jeffrey F. Moley. (2006) Current approaches to medullary thyroid carcinoma, sporadic and familial. Journal of Surgical Oncology 94:8, 737-747
CrossRef75
Carlos Suárez, Juan Pablo Rodrigo, Alfio Ferlito, Rubén Cabanillas, Ashok R. Shaha, Alessandra Rinaldo. (2006) Tumours of familial origin in the head and neck. Oral Oncology 42:10, 965-978
CrossRef76
José G. Guillem, William C. Wood, Jeffrey F. Moley, Andrew Berchuck, Beth Y. Karlan, David G. Mutch, Robert F. Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L. Weber, Francis Giardiello, Miguel A. Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit. (2006) ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Annals of Surgical Oncology 13:10, 1296-1321
CrossRef77
Yoshiki Murakumo, Mayumi Jijiwa, Naoya Asai, Masatoshi Ichihara, Masahide Takahashi. (2006) RET and neuroendocrine tumors. Pituitary 9:3, 179-192
CrossRef78
Christian Piolat, Jean-François Dyon, Nathalie Sturm, Stéphane Pinson, Michel Bost, Pierre-Simon Jouk, Dominique Plantaz, Olivier Chabre. (2006) Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clinical Endocrinology 65:1, 118-124
CrossRef79
G SAKORAFAS, G PEROS, D FARLEY. (2006) Thyroid nodules: Does the suspicion for malignancy really justify the increased thyroidectomy rates?. Surgical Oncology 15:1, 43-55
CrossRef80
Melissa E. Danko, Michael A. Skinner. (2006) Surgical intervention in children with multiple endocrine neoplasia type 2. Current Opinion in Pediatrics 18:3, 312-315
CrossRef81
Wylie Burke, Nancy Press. (2006) Genetics as a tool to improve cancer outcomes: ethics and policy. Nature Reviews Cancer 6:6, 476-482
CrossRef82
Eric Baudin, Jean Paul Travagli, Martin Schlumberger. (2006) How effective is prophylactic thyroidectomy in asymptomatic multiple endocrine neoplasia type 2A?. Nature Clinical Practice Endocrinology & Metabolism 2:5, 256-257
CrossRef83
Andreas Machens, Henning Dralle. (2006) Multiple endocrine neoplasia type 2 and the RET protooncogene: From bedside to bench to bedside. Molecular and Cellular Endocrinology 247:1-2, 34-40
CrossRef84
Alexandra King. (2006) Prophylactic thyroidectomy: effective against medullary thyroid carcinoma in children. Nature Clinical Practice Endocrinology & Metabolism 2:1, 9-9
CrossRef85
Massimo Santoro, Francesca Carlomagno. (2006) Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice Endocrinology & Metabolism 2:1, 42-52
CrossRef86
T FAHEYIII. (2006) Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2ASkinner MA, Moley JA, Dilley WG, et al (Duke Univ, Durham, NC; Washington Univ, St Louis) N Engl J Med 353:1105–1113, 2005§. Yearbook of Surgery 2006, 144-144
CrossRef87
(2005) Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A. New England Journal of Medicine 353:26, 2817-2818
Full Text88
E. Seeman. (2005) Clinical and Basic Research Papers - September 2005 Selections. International Bone and Mineral Society Knowledge Environment 2:10, 1-4
CrossRef89
Moore, Francis D., Dluhy, Robert G., . (2005) Prophylactic Thyroidectomy in MEN-2A — A Stitch in Time?. New England Journal of Medicine 353:11, 1162-1164
Full Text
- Letters
